Climb Bio, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Climb Bio, Inc. now
Current reporting with the operating signal separated from the noise.
Climb Bio, Inc. (CLYM) Discusses Budoprutug and CD19 Opportunity in Immune-Mediated Diseases Transcript
The story matters when it changes Climb Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Climb Bio, Inc. Expands Leadership Team with Appointment of Dr. Edgar D. Charles as CMO and Cindy J. Driscoll as SVP of Finance
The story matters when it changes Climb Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Climb Bio, Inc. Appoints Perrin Wilson, Ph.D. as Chief Business Officer
The story matters when it changes Climb Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest CLYM filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Climb Bio, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →